- Details
- Srikala Sridhar joins Sam Chang in discussing long-term follow-up from the JAVELIN Bladder 100 trial of avelumab first-line maintenance for advanced urothelial carcinoma. The JAVELIN-100 study was conducted on patients with metastatic urothelial carcinoma who had received frontline platinum-based chemotherapy and achieved a disease response. These patients were then randomized to receive either av...
|
- Details
- Sam Chang is joined in conversation by Gopa Iyer, discussing an article in European Urology that examines the predictive nature of FGFR3 wild-type versus mutant-type and its impact on patient response to perioperative chemotherapy in urothelial carcinoma. The study sought to evaluate the association between FGFR3 alterations and response to platinum-based chemotherapy, both in the perioperative as...
|
- Details
- Alicia Morgans is joined by Andrea Necchi in a conversation on the CheckMate 274 trial, the use of biomarkers in the adjuvant setting, and how they can be used to understand the effect of nivolumab. Necchi and colleagues performed an exploratory analysis to assess the association between disease-free survival (DFS) and biomarkers (continuous scale) and estimate treatment-effect hazard ratios for b...
|
- Details
- Andrea Necchi joins Alicia Morgans in a conversation about the FIDES-02 Study. This Phase 1b/2 study evaluated the efficacy and safety of derazantinib, a multi-TKI oral inhibitor that targets FGF receptor genomic alteration 1, 2, 3, and 4 genomic alterations, in patients with metastatic urothelial carcinoma. The focus is metastatic local advanced or metastatic patients with urothelial carcinoma of...
|
- Details
- Michiel Van der Heijden discusses two abstracts on the use of immunotherapy in bladder cancer during his discussion with Alicia Morgans. The first abstract looked at the use of pembrolizumab in patients with non-muscle invasive bladder cancer, specifically those with high-grade TA or T1 disease that is refractory to BCG treatment. The study showed a 43% recurrence-free survival rate at one year, m...
|
- Details
- Petros Grivas joins Alicia Morgans in a discussion on updated results of the phase II TROPHY-U-01 data from cohort 3, looking at the combination of pembrolizumab, anti-PD-1, plus sacituzumab govitecan, an antibody-drug conjugate against Trop-2 evaluated in 41 patients who had early progression resistance to platinum-based chemotherapy as a second-line therapy. Biographies: Petros Grivas, MD, Ph.D....
|
- Details
- Andrea Apolo, head of the bladder cancer section of the genitourinary malignancy branch within the NCI, joins Sam Chang to discuss first-line therapies for patients with advanced and metastatic urothelial carcinoma. Dr. Apolo explains that several clinical trials have been developed to improve outcomes in patients in the first-line setting by combining chemotherapy with checkpoint inhibitors. One...
|
- Details
- Srikala Sridhar joins Petros Grivas in a conversation about the JAVELIN Bladder 100 phase III trial in the front-line setting using immunotherapy to treat advanced urothelial cancer. The study involved patients who received upfront platinum-based chemotherapy and were randomized to receive avelumab every two weeks or supportive care if they had no evidence of disease progression. The trial showed...
|
- Details
- Sam Chang welcomes Shilpa Gupta to discuss the evolving treatment paradigm for advanced urothelial carcinoma, focusing particularly on platinum eligibility for patients. Dr. Gupta traces the progression of treatments, from gemcitabine and carboplatin prior to 2017 to the introduction of two checkpoint inhibitors, atezolizumab and pembrolizumab, in 2017. However, she notes the shift back to platinu...
|
- Details
- Alicia Morgans and Guru Sonpavde discuss the results of Cohort K of the EV-103 trial presented at the 2022 European Society for Medical Oncology (ESMO) Annual Congress. There remains a critical need for effective and tolerable first-line treatment options in locally advanced or metastatic urothelial cancer. In second and later-line settings, both EV and pembrolizumab have independently shown an ov...
|
